ZYDUS LIFESCIENCES
|
ZYDUS LIFESCIENCES Last 5 Year Financial Ratios History
[Consolidated]
| Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 19.37 | 43.82 | 20.84 | 11.49 | 18.05 |
| CEPS(Rs) | 26.92 | 29.68 | 28.08 | 18.28 | 23.93 |
| DPS(Rs) | 6.00 | 2.50 | 3.50 | 3.50 | 3.50 |
| Book NAV/Share(Rs) | 173.08 | 166.01 | 126.88 | 101.33 | 101.43 |
| Tax Rate(%) | 22.70 | 18.03 | 8.07 | 21.39 | 22.26 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 10.53 | 10.74 | 11.72 | 19.51 | 22.62 |
| EBIT Margin(%) | 8.02 | 10.03 | 8.96 | 12.89 | 19.58 |
| Pre Tax Margin(%) | 7.64 | 9.60 | 8.31 | 10.49 | 18.09 |
| PAT Margin (%) | 5.90 | 7.87 | 7.64 | 8.25 | 14.07 |
| Cash Profit Margin (%) | 8.03 | 10.28 | 9.96 | 13.13 | 18.61 |
| Performance Ratios | |||||
| ROA(%) | 7.82 | 9.40 | 9.66 | 5.18 | 9.34 |
| ROE(%) | 11.60 | 15.51 | 18.88 | 11.32 | 19.36 |
| ROCE(%) | 13.64 | 15.30 | 14.38 | 10.02 | 15.89 |
| Asset Turnover(x) | 1.32 | 1.19 | 1.27 | 0.63 | 0.66 |
| Sales/Fixed Asset(x) | 1.88 | 1.69 | 1.69 | 0.88 | 1.05 |
| Working Capital/Sales(x) | 7.57 | 6.92 | 33.78 | 31.96 | 11.39 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.53 | 0.59 | 0.59 | 1.14 | 0.95 |
| Receivable days | 41.75 | 39.94 | 42.92 | 97.49 | 99.21 |
| Inventory Days | 38.39 | 42.95 | 38.08 | 70.13 | 70.33 |
| Payable days | 145.80 | 166.64 | 189.45 | 170.61 | 167.94 |
| Valuation Parameters | |||||
| PER(x) | 25.37 | 7.96 | 21.16 | 23.25 | 19.20 |
| PCE(x) | 18.26 | 11.75 | 15.70 | 14.61 | 14.48 |
| Price/Book(x) | 2.84 | 2.10 | 3.47 | 2.64 | 3.42 |
| Yield(%) | 1.22 | 0.72 | 0.79 | 1.31 | 1.01 |
| EV/Net Sales(x) | 2.92 | 2.57 | 3.39 | 2.41 | 3.25 |
| EV/Core EBITDA(x) | 12.44 | 10.88 | 14.11 | 11.87 | 13.44 |
| EV/EBIT(x) | 18.51 | 13.08 | 18.89 | 18.72 | 16.62 |
| EV/CE(x) | 2.05 | 1.45 | 2.14 | 1.51 | 1.90 |
| M Cap / Sales | 2.89 | 2.36 | 3.13 | 1.92 | 2.70 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 14.08 | 4.90 | 1.06 | 8.26 | 10.59 |
| Core EBITDA Growth(%) | 13.49 | 3.04 | 19.43 | -9.09 | 6.93 |
| EBIT Growth(%) | -8.28 | 14.68 | 40.74 | -28.73 | 5.58 |
| PAT Growth(%) | -13.95 | 5.48 | 87.61 | -36.52 | 4.83 |
| EPS Growth(%) | -55.80 | 110.32 | 81.34 | -36.36 | 4.11 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.07 | 0.25 | 0.35 | 0.77 | 0.76 |
| Current Ratio(x) | 1.81 | 1.55 | 1.11 | 1.05 | 1.16 |
| Quick Ratio(x) | 1.19 | 1.07 | 0.70 | 0.72 | 0.79 |
| Interest Cover(x) | 20.94 | 23.35 | 13.87 | 5.38 | 13.17 |
| Total Debt/Mcap(x) | 0.02 | 0.12 | 0.10 | 0.29 | 0.22 |
Compare Financial Ratios of peers of ZYDUS LIFESCIENCES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| ZYDUS LIFESCIENCES | ₹92,791.8 Cr | 5% | 10.4% | 109.1% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹365,311.0 Cr | 3% | 2.3% | 68.2% | Stock Analytics | |
| CIPLA | ₹108,623.0 Cr | 2.5% | 0.4% | 71.7% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹99,134.3 Cr | -0.2% | -4.9% | 40.3% | Stock Analytics | |
| DIVIS LABORATORIES | ₹97,408.4 Cr | -1.6% | -7% | 23.8% | Stock Analytics | |
| MANKIND PHARMA | ₹93,565.4 Cr | NA | NA | NA | Stock Analytics | |
ZYDUS LIFESCIENCES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| ZYDUS LIFESCIENCES | 5% |
10.4% |
109.1% |
| SENSEX | -2.6% |
-0% |
21% |
You may also like the below Video Courses
